MD Anderson, Foundation Medicine, team up to improve targeted therapies in metastatic disease

The University of Texas MD Anderson Cancer Center announced today an alliance with Cambridge, MA-based Foundation Medicine. The teams are opening a randomized-controlled trial to determine whether targeted therapies selected based on tumor molecular profiling compared with treatment not selected on this basis results in longer progression-free survival in patients with advanced disease.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news